Otros idiomas Omega Therapeutics, Inc.

Acciones

OMGA

US68217N1054

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 01/07/2024			Varia. Cinco días.	Varia. 1 de enero.
2,25 ^USD	+8,70 %		-7,02 %	-25,25 %

24/06	Omega Therapeutics, Inc. nombra a Richard N. Kender miembro del Consejo de Administración	CI
18/06	OMEGA THERAPEUTICS, INC. : recomendación de compra de Raymond James	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors	24/06
Omega Therapeutics, Inc. Appoints Richard N. Kender to Board of Directors	24/06
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer	13/06
Omega Therapeutics, Inc. Announces Termination of Yan Moore as Chief Medical Officer	30/05
Omega Therapeutics To Participate In Two Upcoming Investor Conferences	30/05
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer	29/05
Omega Therapeutics, Inc. Appoints Kaan Certel, Ph.D., as Chief Business Officer	29/05
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers	08/05
Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress	06/05
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting	23/04
Omega Therapeutics CFO Joshua Reed to Depart	16/04
Omega Therapeutics, Inc. Announces Executive Changes, Effective as of May 31, 2024	16/04
Omega Therapeutics, Inc. Designates Barbara Chan as Principal Accounting Officer, Effective as of May 31, 2024	16/04
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control	09/04
Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control	09/04
Omega Therapeutics Cuts Headcount by 35%, Narrows Q4 Loss	28/03
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update	28/03
Omega Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Omega Therapeutics, Inc.

Acciones

OMGA

US68217N1054

Otros idiomas

Filtros